| Sedación en terapia intensiva: ¿Es la dexmedetomidina la mejor elección? |
Sedation in intensive care unit: Is Dexmedetomidine the best choice?.
Anand VG.
Int J Crit Illn Inj Sci [serial online] 2012 [cited 2012 Apr 11];2:3-5.
Dexmedetomidine, since its approval in 1999, seems to gain a place in the intensive care unit (ICU) as a safer sedative agent, deftly replacing its predecessors like propofol, benzodiazepines etc. It combines the property of both sedation and analgesia, without compromising on respiration and co-operation. Only hitch seems to be the hemodynamic effect, which has also been proved statistically insignificant. Still, its clinical significance cannot be overlooked.
http://www.ijciis.org/text.asp?2012/2/1/3/94866
|
| Papel actual de la dexmedetomidina en anestesia clínica y terapia intensiva |
Current role of dexmedetomidine in clinical anesthesia and intensive care.
Kaur M, Singh PM.
Anesth Essays Res [serial online] 2011 [cited 2012 Apr 9];5:128-33.
Dexmedetomidine is a new generation highly selective α 2-adrenergic receptor (α 2-AR) agonist that is associated with sedative and analgesic sparing effects, reduced delirium and agitation, perioperative sympatholysis, cardiovascular stabilizing effects, and preservation of respiratory function. The aim of this review is to present the most recent topics regarding the advantages in using dexmedetomidine in clinical anesthesia and intensive care, while discussing the controversial issues of its harmful effects.
Keywords: Dexmedetomidine, intensive care unit sedation, α 2-adrenergic receptor agonist
http://www.aeronline.org/text.asp?2011/5/2/128/94750
|
|
No hay comentarios:
Publicar un comentario